NCT05330858 is a Phase 1 clinical trial of ESK-001 in Pharmacokinetics, sponsored by Alumis Inc.

Who is sponsoring NCT05330858?

NCT05330858 is sponsored by Alumis Inc.

What drugs are being tested in NCT05330858?

Interventions in NCT05330858: ESK-001, Rabeprazole.

What condition does NCT05330858 study?

NCT05330858 studies Pharmacokinetics.

Is NCT05330858 still recruiting?

NCT05330858 is currently completed. Last updated 9 May 2023.

Last reviewed 2023-05-09 · How we verify

NCT05330858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Completed Phase 1 Last updated 9 May 2023

What this trial tests

Phase 1 trial testing ESK-001 in Pharmacokinetics in 14 participants. Completed in 20 September 2022.

Timeline

17 March 2022

Primary endpoint
30 June 2022

20 September 2022

Quick facts

Lead sponsor	Alumis Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	14
Start date	17 March 2022
Primary completion	30 June 2022
Estimated completion	20 September 2022
Sites	1 location across United States

Drugs / interventions tested

ESK-001 — full drug profile →
Rabeprazole — full drug profile →

Conditions studied

Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

Alumis Inc — full company profile →

Who can join

Adults 18 to 60, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ESK-001

Trials testing the same drug.

NCT06962774 — An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and · Phase 1 · completed
NCT07378579 — An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 · Phase 1 · completed
NCT05953688 — POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU · Phase 2 · terminated
NCT05600036 — A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis · Phase 2 · completed

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting

Other Alumis Inc trials

Trials by the same sponsor.

NCT06962774 — An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and · Phase 1 · completed
NCT06588738 — A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 · Phase 3 · completed
NCT06586112 — A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis · Phase 3 · completed
NCT07378579 — An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 · Phase 1 · completed
NCT07442149 — An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05330858 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alumis Inc
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing